The respiratory threat posed by multidrug resistant Gram-negative bacteria

Respirology

Volumn 22, Issue 7, 2017, Pages 1288-1299

  Rodrigo Troyano, Ana ^a,b   Sibila, Oriol ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

bronchiectasis; chronic obstructive pulmonary disease; multidrug resistance; pneumonia; respiratory infections

Indexed keywords

ANTIBIOTIC RESISTANCE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; COMMUNITY ACQUIRED INFECTION; CROSS INFECTION; GRAM NEGATIVE BACTERIUM; MICROBIOLOGY; PATHOGENICITY;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 85021829726     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.13115     Document Type: Review

References (84)

1. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl. Vital Stat. Rep. 2009; 57: 1–134.
2. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin. Pharmacother. 2014; 15: 1351–70.
3. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J; Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 2008; 46: 155–64.
4. Solomon SL, Oliver KB. Antibiotic resistance threats in the United States: sleeping back from the brink. Am. Fam. Physician 2014; 12: 938–41.
5. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009; 48: 1–12.
6. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406: 959–64.
7. Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995; 15: 279–91.
8. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001; 9: 34–9.
9. Lynch JP. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001; 119: 373–84.
10. Vincent J-L. Nosocomial infections in adult intensive-care units. Lancet 2003; 361: 2068–77.
11. Sibila O, Laserna E, Maselli DJ, Fernandez JF, Mortensen EM, Anzueto A, Waterer G, Restrepo MI. Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia. Respirology 2015; 20: 660–6.
12. Nagaki M, Shimura S, Tanno Y, Ishibashi T, Sasaki H, Takishima T. Role of chronic Pseudomonas aeruginosa infection in the development of bronchiectasis. Chest 1992; 102: 1464–9.
13. Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995; 108: 955–61.
14. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 2008; 29: 1099–106.
15. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, Schlaeffer F, Sherf M. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect. Control Hosp. Epidemiol. 2009; 30: 972–6.
16. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect. 2006; 12: 826–36.
17. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012; 18: 268–81.
18. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44: S27–72.
19. Luna CM, Famiglietti A, Absi R, Videla AJ, Nogueira FJ, Fuenzalida AD, Gené RJ. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118: 1344–54.
20. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML et al.; Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: iii1–55.
21. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 388–416.
22. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, Imaizumi K, Sato T, Hasegawa Y. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 2009; 135: 633–40.
23. Garcia-Vidal C, Viasus D, Roset A, Adamuz J, Verdaguer R, Dorca J, Gudiol F, Carratalà J. Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clin. Microbiol. Infect. 2011; 17: 1659–65.
24. Fukuyama H, Yamashiro S, Tamaki H, Kishaba T. A prospective comparison of nursing- and healthcare-associated pneumonia (NHCAP) with community-acquired pneumonia (CAP). J. Infect. Chemother. 2013; 19: 719–26.
25. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin. Infect. Dis. 2014; 58: 330–9.
26. Sibila O, Rodrigo-Troyano A, Shindo Y, Aliberti S, Restrepo MI. Multidrug-resistant pathogens in patients with pneumonia coming from the community. Curr. Opin. Pulm. Med. 2016; 22: 219–26.
27. Kang C-I, Song J-H, Oh WS, Ko KS, Chung DR, Peck KR; Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group. Clinical outcomes and risk factors of community-acquired pneumonia caused by Gram-negative bacilli. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 657–61.
28. Falguera M, Carratalà J, Ruiz-Gonzalez A, Garcia-Vidal C, Gazquez I, Dorca J, Gudiol F, Porcel JM. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology 2009; 14: 105–11.
29. Von Baum H, Welte T, Marre R, Suttorp N, Ewig S; CAPNETZ study group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur. Respir. J. 2010; 35: 598–615.
30. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, Choudhury G, Hill AT. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin. Infect. Dis. 2011; 53: 107–13.
31. Li X-J, Li Q, Si L-Y, Yuan Q-Y. Bacteriological differences between COPD exacerbation and community-acquired pneumonia. Respir. Care 2011; 56: 1818–24.
32. Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, Tarsia P, Mantero M, Blasi F. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin. Infect. Dis. 2012; 54: 470–8.
33. Ma HM, Ip M, Woo J, Hui DSC, Lui GCY, Lee NLS, Chan PKS, Rainer TH. Risk factors for drug-resistant bacterial pneumonia in older patients hospitalized with pneumonia in a Chinese population. QJM 2013; 106: 823–9.
34. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2013; 188: 985–95.
35. Maruyama T, Fujisawa T, Okuno M, Toyoshima H, Tsutsui K, Maeda H, Yuda H, Yoshida M, Kobayashi H, Taguchi O et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin. Infect. Dis. 2013; 57: 1373–83.
36. Wu C-L, Ku S-C, Yang K-Y, Fang W-F, Tu C-Y, Chen C-W, Hsu K-H, Fan W-C, Lin M-C, Chen W et al. Antimicrobial drug-resistant microbes associated with hospitalized community-acquired and healthcare-associated pneumonia: a multi-center study in Taiwan. J. Formos. Med. Assoc. 2013; 112: 31–40.
37. Prina E, Ranzani OT, Polverino E, Cillóniz C, Ferrer M, Fernandez L, Puig de la Bellacasa J, Menéndez R, Mensa J, Torres A. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann. Am. Thorac. Soc. 2015; 12: 153–60.
38. Cilloniz C, Gabarrus A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, Niederman MS, Torres A. Community-Acquired Pneumonia due to Multidrug and non-Multidrug resistant Pseudomonas aeruginosa. Chest 2016; 150: 415–25.
39. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch. Intern. Med. 2002; 162: 1849–58.
40. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 2016; 63: e61–111.
41. Guzek A, Korzeniewski K, Tomaszewski D, Rybicki Z, Zwolińska E. Bacteriological assessment of pneumonia caused by Gram-negative bacteria in patients hospitalized in intensive care unit. Adv. Exp. Med. Biol. 2017; 955: 39–46.
42. Koulenti D, Lisboa T, Brun-Buisson C, Krueger W, Macor A, Sole-Violan J, Diaz E, Topeli A, DeWaele J, Carneiro A et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit. Care Med. 2009; 37: 2360–9.
43. Behnia M, Logan SC, Fallen L, Catalano P. Nosocomial and ventilator-associated pneumonia in a community hospital intensive care unit: a retrospective review and analysis. BMC. Res. Notes 2014; 7: 232.
44. Chien J-Y, Hsueh P-R, Yu C-J, Yang P-C. The evolution of drug-resistant microorganisms in patients with prolonged mechanical ventilation. Am. J. Infect. Control 2009; 37: 231–6.
45. Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG, Heyland DK; Canadian Critical Care Trials Group. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J. Crit. Care 2008; 23: 18–26.
46. Peña C, Gómez-Zorrilla S, Oriol I, Tubau F, Dominguez MA, Pujol M, Ariza J. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur. J. Clin. Microbiol. Infect. Dis. 2013; 32: 413–20.
47. Di Pasquale M, Ferrer M, Esperatti M, Crisafulli E, Giunta V, Li Bassi G, Rinaudo M, Blasi F, Niederman M, Torres A. Assessment of severity of ICU-acquired pneumonia and association with etiology. Crit. Care Med. 2014; 42: 303–12.
48. Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, Antonelli M, Welte T, Clair B, Ostermann H et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit. Care 2015; 19: 219.
49. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.
50. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379: 1341–51.
51. Monsó E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, Ausina V. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am. J. Respir. Crit. Care Med. 1995; 152: 1316–20.
52. Zalacain R, Sobradillo V, Amilibia J, Barrón J, Achótegui V, Pijoan JI, Llorente JL. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur. Respir. J. 1999; 13: 343–8.
53. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am. J. Med. 2000; 109: 288–95.
54. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 173: 991–8.
55. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759–64.
56. Lin SH, Kuo PH, Hsueh PR, Yang PC, Kuo SH. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 2007; 12: 81–7.
57. Garcia-Vidal C, Almagro P, Romani V, Rodriguez-Carballeira M, Cuchi E, Canales L, Blasco D, Heredia JL, Garau J. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur. Respir. J. 2009; 34: 1072–8.
58. Engler K, Mühlemann K, Garzoni C, Pfahler H, Geiser T, von Garnier C. Colonisation with Pseudomonas aeruginosa and antibiotic resistance patterns in COPD patients. Swiss Med. Wkly. 2012; 142: w13509.
59. Domenech A, Puig C, Martí S, Santos S, Fernández A, Calatayud L, Dorca J, Ardanuy C, Liñares J. Infectious etiology of acute exacerbations in severe COPD patients. J. Infect. 2013; 67: 516–23.
60. Gallego M, Pomares X, Espasa M, Castañer E, Solé M, Suárez D, Monsó E, Montón C. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm. Med. 2014; 14: 103.
61. Ma X, Cui J, Wang J, Chang Y, Fang Q, Bai C, Zhou X, Zhou H, Feng H, Wang Y et al. Multicentre investigation of pathogenic bacteria and antibiotic resistance genes in Chinese patients with acute exacerbation of chronic obstructive pulmonary disease. J. Int. Med. Res. 2015; 43: 699–710.
62. Sibila O, Garcia-Bellmunt L, Giner J, Rodrigo-Troyano A, Suarez-Cuartin G, Torrego A, Castillo D, Solanes I, Mateus EF, Vidal S et al. Airway mucin 2 is decreased in patients with severe chronic obstructive pulmonary disease with bacterial colonization. Ann. Am. Thorac. Soc. 2016; 13: 636–42.
63. Rodrigo-Troyano A, Suarez-Cuartin G, Peiró M, Barril S, Castillo D, Sanchez-Reus F, Plaza V, Restrepo MI, Chalmers JD, Sibila O. Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirology 2016; 21: 1235–42.
64. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114–21.
65. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117: 380S–5S.
66. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–8.
67. Ko FWS, Ip M, Chan PKS, Fok JPC, Chan MCH, Ngai JC, Chan DPS, Hui DSC. A 1-year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. Chest 2007; 131: 44–52.
68. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005–12.
69. Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014; 384: 691–702.
70. McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2013; 188: 647–56.
71. Cole PJ. Inflammation: a two-edged sword – the model of bronchiectasis. Eur. J. Respir. Dis. Suppl. 1986; 147: 6–15.
72. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir. Med. 2007; 101: 1633–8.
73. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur. Respir. J. 2009; 34: 843–9.
74. Hester KLM, Macfarlane JG, Tedd H, Jary H, McAlinden P, Rostron L, Small T, Newton JL, De Soyza A. Fatigue in bronchiectasis. QJM 2012; 105: 235–40.
75. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, Serisier DJ. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013; 68: 731–7.
76. Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir. Med. 2014; 108: 287–96.
77. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ et al. The Bronchiectasis Severity Index. An international derivation and validation study. Am. J. Respir. Crit. Care Med. 2014; 189: 576–85.
78. Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A, Fardon TC, Finch S, Mateus EF, Garcia-Bellmunt L, Castillo D, Vidal S, Sanchez-Reus F et al. Secreted mucins and airway bacterial colonization in non-CF bronchiectasis. Respirology 2015; 20: 1082–8.
79. Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, Dicker A, Wrobel K, Elborn JS, Walker B et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am. J. Respir. Crit. Care Med. 2017; 195: 1384–93.
80. McDonnell MJ, Aliberti S, Goeminne PC, Restrepo MI, Finch S, Pesci A, Dupont LJ, Fardon TC, Wilson R, Loebinger MR et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir. Med. 2016; 4: 969–79.
81. Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 2015; 12: 1602–11.
82. Martinez-Garcia MA, de Gracia J, Vendrell Relat M, Giron R-M, Maiz Carro L, de la Rosa Carrillo D, Olveira C. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur. Respir. J. 2014; 43: 1357–67.
83. Polverino E, Cilloniz C, Menendez R, Gabarrus A, Rosales-Mayor E, Alcaraz V, Terraneo S, Puig de la Bella Casa J, Mensa J, Ferrer M et al. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. J. Infect. 2015; 71: 28–36.
84. Suarez-Cuartin G, Feliu A, Rodrigo-Troyano A, Sanchez-Reus F, Castillo D, Plaza V, Restrepo MI, Aliberti S, Chalmers JD, Sibila O. Exacerbations of bronchiectasis requiring hospitalization; clinical characteristics and outcomes. Eur. Respir. J. 2016; 48: 1550.